Table 1.
Clinical and demographic characteristics of people living with HIV at six sites across the United States by myocardial infarction type
| Characteristic | No MI N=27,866 N (%) |
T1MI* N=462 N (%) |
T2MI N=413 N (%) |
P-value^ |
|---|---|---|---|---|
| Age, years median (IQR) | <0.001 | |||
| 47 (38,55) | 52 (46,58) | 50 (43,56) | ||
| Age, years by decade | <0.001 | |||
| <30 | 2254 (8) | 2 (<1) | 20 (5) | |
| 30–39 | 6101 (22) | 30 (6) | 47 (11) | |
| 40–49 | 8187 (29) | 152 (33) | 134 (32) | |
| 50–59 | 7816 (28) | 189 (41) | 147 (36) | |
| 60–69 | 2935 (11) | 68 (15) | 45 (11) | |
| ≥70 | 573 (2) | 21 (5) | 20 (5) | |
| Sex | <0.001 | |||
| Male | 22561 (81) | 393 (85) | 301 (73) | |
| Race/Ethnicity | <0.001 | |||
| White | 11529 (41) | 225 (49) | 106 (26) | |
| African American | 11245 (40) | 175 (38) | 264 (64) | |
| Hispanic | 3605 (13) | 45 (10) | 34 (8) | |
| Other/unknown | 1487 (5) | 17 (4) | 9 (2) | |
| HIV Transmission Risk Factor | <0.001 | |||
| Heterosexual | 7071 (25) | 106 (23) | 123 (30) | |
| Men who have sex with men | 14427 (52) | 239 (52) | 127 (31) | |
| Injection drug use | 5018 (18) | 97 (21) | 147 (36) | |
| Other/unknown | 1350 (5) | 20 (4) | 16 (4) | |
| Antiretroviral therapy | <0.001 | |||
| Yes | 22,100 (79) | 390 (84) | 298 (72) | |
| CD4 count closest to event (cells/μl) | <0.001 | |||
| 0–200 | 4480 (16) | 92 (20) | 170 (41) | |
| 201–350 | 4107 (15) | 82 (18) | 75 (18) | |
| >350 | 19199 (69) | 287 (62) | 168 (41) | |
| Nadir CD4 cell count (cells/μl) | 0.06 | |||
| Median (IQR) | 223 (70,390) | 150 (41,298) | 98 (17,242) | |
| HIV-1 RNA closest to event (copies/ml) | <0.001 | |||
| <500 | 21181 (76) | 339 (74) | 229 (55) | |
| 500–100,000 | 4900 (18) | 97 (21) | 121 (29) | |
| >100,000 | 1617 (6) | 25 (5) | 63 (15) | |
| Lipid Levels mean (mean, SD) | ||||
| Total Cholesterol (mg/dL) | 172 (42) | 188 (53) | 164 (58) | <0.001 |
| HDL (mg/dL) | 46 (16) | 41 (14) | 43 (20) | 0.06 |
| LDL (mg/dL) | 98 (34) | 108 (41) | 86 (39) | <0.001 |
| Triglycerides | 156 (132) | 213 (183) | 192 (223) | 0.2 |
| Statin use | <0.001 | |||
| Yes | 5403 (19) | 228 (49) | 103 (25) | |
| Blood pressure (mean, SD) | ||||
| Systolic (mmHg) | 126 (16) | 131 (20) | 129 (23) | 0.2 |
| Diastolic (mmHg) | 79 (11) | 80 (13) | 79 (14) | 0.1 |
| Anti-hypertensive medication use | 0.3 | |||
| Yes | 10685 (39) | 323 (70) | 273 (67) | |
| Diabetes | 0.3 | |||
| Yes | 3429 (12) | 113 (24) | 113 (27) | |
| Ever smoking | 0.3 | |||
| Yes | 10152 (36) | 216 (47) | 180 (44) | |
| Body mass index (mean, SD) | <0.001 | |||
| BMI (kg/m2) | 27 (6) | 27 (6) | 25 (6) | |
| Risk Score (mean, SD) | 0.7 | |||
| ASCVD (%10 year event risk) | 8 (10) | 14 (12) | 14 (14) |
*
T1MI also includes patients with coronary interventions
^
Comparing T1MI to T2MI
Demographic and clinical characteristics at time of MI or at end of follow-up
MI: myocardial infarctions; T1MI: type 1 myocardial infarction; T2MI type 2 myocardial infarctions